SCHEMBL6843429

SCHEMBL6843429

CCCCCCCCCCN(CC(=O)NO)S(=O)(=O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.59
BMP1 P13497 1/20 0.52
MMP3 P08254 3/20 0.51
HDAC1 Q13547 4/20 0.46
HDAC3 O15379 3/20 0.46
HDAC2 Q92769 3/20 0.46
NCOR2 Q9Y618 3/20 0.46
HDAC8 Q9BY41 2/20 0.46
MMP1 P03956 7/20 0.45
MMP13 P45452 7/20 0.45
MMP9 P14780 3/20 0.45
MMP7 P09237 4/20 0.45
MMP12 P39900 4/20 0.45
ACE P12821 2/20 0.45
EPHX2 P34913 1/20 0.45
MMP8 P22894 3/20 0.44
MMP2 P08253 2/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ICMT O60725 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8037741 1.00 CNR2 (0.59) CNR2BMP1MMP3HDAC1HDAC3
SCHEMBL8038065 1.00 CNR2 (0.59) CNR2BMP1MMP3HDAC1HDAC3
SCHEMBL9307806 0.86 CNR2 (0.71) CNR2EPHX2ICMTALBMEN1
SCHEMBL8038085 0.85 BMP1 (0.69) CNR2BMP1MMP3HDAC1MMP1
SCHEMBL8027608 0.85 MMP3 (0.53) CNR2BMP1MMP3HDAC1HDAC3
SCHEMBL8027595 0.85 BMP1 (0.69) CNR2BMP1MMP3HDAC1MMP1
SCHEMBL8038049 0.85 BMP1 (0.62) CNR2BMP1MMP3HDAC1HDAC3
SCHEMBL8039632 0.85 MMP3 (0.57) BMP1MMP3HDAC1HDAC3HDAC2
SCHEMBL6411529 0.82 BMP1 (0.53) CNR2BMP1MMP3HDAC1HDAC3
SCHEMBL8041116 0.82 MMP2 (0.55) MMP3MMP1MMP13MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176393-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2004-09-09 US disclosed
US-6124329-A AN ENZYME INHIBITOR FOR THE TREATMENT OR PROPHYLAXIS OF TISSUE BREAKDOWN, FOR EXAMPLE RHEUMATOID ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR, MULTIPLE SCLEROSIS BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2000-09-26 US disclosed
EP-0766664-B1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARM (GB) 2000-04-05 EP disclosed
EP-0766664-A2 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-04-09 EP disclosed
WO-1995035275-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176393-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 CNR2 4148/4885BMP1 922/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.